You are here

AAD

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

Endpoints

Tue, 03/21/23 - 10:06 am

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

EP Vantage

Tue, 03/21/23 - 09:54 am

hidradenitis suppurativa

AAD 2020 – Leo’s eczema wildcard proves tame

EP Vantage

Fri, 06/12/20 - 08:02 pm

atopic dermatitis